learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
forResearch
5 / 1000+ results
research Up-Regulation of Androgen Receptor by Heat Shock Protein 27 and miR-1 Induces Pathogenesis of Androgenic Alopecia
Higher levels of heat shock protein 27 and lower levels of miR-1 can increase AR levels, leading to hair loss in men.
research DHT and E2 Synthesis-Related Proteins and Receptors Expression in Male Yak Skin During Different Hair Follicle Stages
Male yak hair growth is influenced by DHT synthesis, which is promoted by 5α-red1 and AR during growth phases, while E2 may inhibit growth through ERα.
research Male-Pattern Baldness, Common Latent Viruses, and Microcompetition
Common latent viruses might contribute to male-pattern baldness by disrupting cell processes that normally suppress hair loss-related proteins.
research Stem Cell-Derived Motor Neurons from Spinal and Bulbar Muscular Atrophy Patients
The study suggests that motor neurons created from stem cells of patients with spinal and bulbar muscular atrophy show signs of the disease, including changes in protein levels and cell functions.
research Regional Difference in Sebum Production by Androgen Susceptibility in Human Facial Skin
The T-zone on the face has more androgen receptors and produces more oil than the U-zone.
Community Join
5 / 414 resultscommunity Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community Kintor’s GT20029 Phase 1 success
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
community GT20029 Anageninc Market Availability
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
community What are you thinks about new treatment methods and development in hair lose ? such as; Breezula
The conversation discusses new hair loss treatments, mentioning Breezula and a promising treatment called pyrilutamide.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.